Is GRFS or GSK more undervalued in 2026?

CirclFi compares Grifols, S.A. (GRFS) and GSK plc (GSK) using 13 institutional-grade valuation models. GRFS has a Quality of Company score of 1.7/10 while GSK scores 8.7/10.

Which is a better buy — GRFS or GSK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GRFS and GSK valuations compare?

GRFS at $7.85 and GSK at $50.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GRFS vs GSK Valuation Comparison 2026 — Intrinsic Value Analysis

GRFS

Pharmaceutical Preparations

Grifols, S.A.

Quality

1.7

out of 10

Value Trap

—

Price

$7.85

Last close

Models

13/13

Active

GSK

Pharmaceutical Preparations

GSK plc

Quality

8.7

out of 10

Value Trap

SAFE

Price

$50.54

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	GRFS Fair Value	GRFS Upside	GSK Fair Value	GSK Upside
Bayesian DCF	Intrinsic	$2.40	-69.4%	$43.74	-13.5%
Earnings Power Value	Intrinsic	$3.00	-62.8%	$56.37	+11.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GRFS vs GSK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GRFS vs GSK — Which Stock Is More Undervalued?

GSK scores higher with a 8.7/10 quality rating vs GRFS's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Grifols, S.A. (GRFS) and GSK plc (GSK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GRFS currently trades at $7.85 with a QOC of 1.7/10, while GSK trades at $50.54 with a QOC of 8.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).